~~<i id='3A6F72CCEA'><strike id='3A6F72CCEA'><tt id='3A6F72CCEA'><pre id='3A6F72CCEA'></pre></tt></strike></i>~~

Home» explore» fashion

fashion

author：knowledge 2025-10-02 12:37:47 Page View：81945

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead
Next article： Anesthesiologist group: stop taking Ozempic before surgery

focus

Hollywood unions extend contract negotiations for actors

1:36HollywoodwritersandtheirsupportersfromtheSAGAFTRAactors'unionwalkthepicketlineoutsideWarnerBrosS

Court strikes down limits on filming of police in Arizona

FILE-PhoenixPolicestandinfrontofpoliceheadquartersonMay30,2020,inPhoenix,waitingforprotestersmarchin

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

How artificial intelligence is being used to detect, treat cancer

3:26Alaboratorytechnicianconductsartificialintelligence(AI)-basedcervicalcancerscreeningatatestfacil